Literature DB >> 26582162

Responding to a rebuttal letter concerning the BERVOLT study.

Tom Kornhauser1, Adiel Barak2.   

Abstract

Keywords:  Bevacizumab; Branch retinal vein occlusion; Central retinal vein occlusion; Retinal vein occlusion

Mesh：

Substances：

Year:  2015        PMID： 26582162     DOI： 10.1007/s00417-015-3217-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.

Authors:  Robert P Finger; Peter Wiedemann; Francisca Blumhagen; Karin Pohl; Frank G Holz
Journal:  Acta Ophthalmol       Date:  2012-11-22       Impact factor: 3.761

2.  Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.

Authors:  Salomon Y Cohen; Lise Dubois; Ramin Tadayoni; Franck Fajnkuchen; Sylvia Nghiem-Buffet; Corinne Delahaye-Mazza; Brigitte Guiberteau; Gabriel Quentel
Journal:  Am J Ophthalmol       Date:  2009-05-24       Impact factor: 5.258

3.  Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.

Authors:  Salomon Y Cohen; Gerard Mimoun; Hassiba Oubraham; Alain Zourdani; Christian Malbrel; Stephane Queré; Véronique Schneider
Journal:  Retina       Date:  2013-03       Impact factor: 4.256

4.  [Access to healthcare services for elderly patients with neovascular age-related macular degeneration].

Authors:  R P Finger; F G Holz
Journal:  Ophthalmologe       Date:  2012-05       Impact factor: 1.059
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.